Clinical Report: Combination Therapy in Myopia Control
Overview
Combination therapy is increasingly considered for myopia control, particularly in children with ongoing progression despite monotherapy. It is essential to identify specific cases where escalation is warranted.
Background
Myopia is a growing concern, particularly in children, as it can lead to significant visual impairment. Clinicians have various treatment options, including atropine and optical interventions, but determining when to escalate treatment remains a challenge. Understanding the risk factors for progression is crucial for effective management.
Data Highlights
No specific numerical data provided in the source material.
Key Findings
Combination therapy should be a targeted escalation strategy rather than a default response to progression.
Children with rapid axial elongation, high axial length percentiles, or strong family histories may require combination therapy.
A structured audit of treatment adherence and measurement consistency is essential before considering combination therapy.
Most studies on combination therapy focus on 0.01% atropine with optical interventions like orthokeratology.
Combination therapy generally shows better outcomes than monotherapy with 0.01% atropine alone.
Clinical Implications
Clinicians should assess each child's risk factors and treatment adherence before considering combination therapy. A structured audit can help differentiate between true treatment failure and apparent failure due to measurement inconsistencies or poor adherence.
Conclusion
Combination therapy in myopia control should focus on children who exhibit strong progression signals and ensuring that current treatments are appropriately managed.
